Telix Reports Third Quarter 2026 Financial Performance
Key Highlights
- ➤Group revenue $245 million, up 19% year over year in Q3 2026
- ➤Precision Medicine revenue $201 million, up 30% year over year
- ➤FDA approved Pixclara for glioma imaging, with first commercial doses in September
- ➤Telix announced $1.65 billion merger with ITM, plus up to $700 million contingent consideration
- ➤FY 2026 revenue and other income expected to exceed $1 billion
Expert Statements
Christian Behrenbruch, Managing Director and Group CEO of Telix Pharmaceuticals
“Demand for both Gozellix and Illuccix remained strong during the quarter, with U.S. dose volumes increasing 1% quarter-over-quarter, in line with our expectations and reflecting expected summer seasonality.”
Christian Behrenbruch, Managing Director and Group CEO of Telix Pharmaceuticals
“We are pleased by the strong September exit run rate, supporting our confidence in delivering over 25% Precision Medicine revenue growth in 2026.”
Christian Behrenbruch, Managing Director and Group CEO of Telix Pharmaceuticals
“We achieved an important milestone with the FDA approval of Pixclara, expanding our commercial portfolio, establishing a presence in neuro-oncology and further diversifying our revenue base.”
Christian Behrenbruch, Managing Director and Group CEO of Telix Pharmaceuticals
“During the quarter, we announced a transformative merger with ITM, creating a leading vertically integrated radiopharmaceutical company with one of the industry's broadest therapeutic pipelines and expanded isotope production and global manufacturing capabilities.”
Christian Behrenbruch, Managing Director and Group CEO of Telix Pharmaceuticals
“This is aligned with our long-term growth strategy reinforcing our ability to reliably serve patients at scale.”
MELBOURNE, Australia and INDIANAPOLIS, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a financial update on its commercial and operational performance for the quarter ended September 30, 2026 (Q3 2026).
Q3 2026 Highlights(1) * Group revenue of US$245 million increased 19% over the prior corresponding quarter (Q3 2025) driven by continued strong demand for the commercial portfolio, in line with expectations. September sales drove a higher quarterly exit rate indicating continued strength in underlying demand for Telix's PSMA products. * Precision Medicine revenue of US$201 million, increased 30% over the prior corresponding quarter, driven by both Gozellix® and Illuccix®(2). Telix's commercial PSMA-PET imaging(3) portfolio continued to strengthen its market position, driven by strong demand for our clinically differentiated products. * U.S. Food and Drug Administration (FDA) approved Pixclara®(4) for glioma imaging, marking a significant milestone and establishing the first approved imaging agent for this indication in the U.S.(5). The first commercial doses were administered in September 2026(6). * BiPASS®, a Phase 3 study evaluating pre-biopsy prostate cancer detection, completed enrollment(7), with the FDA supporting an NDA pathway and granting Fast Track Designation(8). * Telix announced a merger with Isotope Technologies Munich SE (ITM). The merger creates a leading radiopharmaceutical platform with one of the industry's broadest therapeutics pipelines, supported by best-in-class isotope production, manufacturing, and supply chain capabilities(9). * Telix reaffirmed that FY 2026 revenue and other income is expected to be in excess of US$1 billion, with revenue tracking in line with upper end of FY 2026 guidance of US$950 million to US$970 million plus US$40 million of other income. The Company has also revised its FY 2026 R&D expenditure guidance range to US$240 million to US$260 million. Q3 2026 Revenue
Get started
Create a free account to read the full story.